Final Results to 30th June 2022

FLLYR

Fri, Sep 30 2022 08:30 am

LONDON STOCK EXCHANGE ANNOUNCEMENT

JPMORGAN GLOBAL GROWTH & INCOME PLC

ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 30TH JUNE 2022

Legal Entity Identifier: 5493007C3I0O5PJKR078

Information disclosed in accordance with DTR 4.2.2

JPMorgan Global Growth & Income plc (the 'Company') announces its results for the year ended 30th June 2022.

CHAIRMAN'S STATEMENT

First, I would like to extend a warm welcome to all shareholders in the Company. Many of you have been long-term investors in the Company and I very much welcome those of you who previously held shares in The Scottish Investment Trust PLC ('SCIN').

Combination with SCIN

The combination with SCIN, effected by way of a scheme of reconstruction of SCIN, was completed on 1st September 2022, following shareholders of both companies voting in favour of the combination. This combination brings together two investment trust companies with similar objectives that have both been in existence since 1887. We look forward to providing our shareholders with the benefits of economies of scale from the enlarged asset base, in particular, an enhanced profile, greater liquidity in the Company's shares and cost efficiencies.

On behalf of the Board, I would like to extend our thanks to our Manager and our advisors for their support and diligence in completing the Company's combination with SCIN.

Further details about the combination can be found in note 25 on page 87 of the full 2022 Annual Report, which details the post balance sheet date events. The financial information in this annual report is as at 30th June 2022 and excludes the combination with SCIN.

At the time of writing (at 26th September 2022), the net asset value of your enlarged Company is £1,300,840,375.

Please refer the PDF to view the full announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.